Antitrust Antitrust

Comment: Aspen settlement sees EU extract broad pricing changes without full-blown probe

By Nicholas Hirst
  • 14 Jul 2020 11:58
  • 14 Jul 2020 15:25

Aspen Pharmacare's high drug prices could have been the hook for a landmark decision showing how EU competition law comes out swinging against dominant companies imposing eye-watering costs on the public.

Instead, regulators opted for a peace deal that has the merit of being unusually broad — and should still

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News